Liquidia (LQDA) Stock News, May-Oct 2025

Liquidia Corporation (NASDAQ: LQDA) announced two upcoming oral presentations at the CHEST 2025 annual meeting in Chicago from October 19-22, 2025. The presentations will showcase new data from the company's ASCENT trial focusing on LIQ861 DPI treprostinil in PH-ILD patients.

The first presentation by Dr. Dan Lachant will discuss changes in cardiac effort in Pulmonary Hypertension-Interstitial Lung Disease patients. The second presentation by Dr. Nicholas Kolaitis will cover safety and exploratory efficacy data of LIQ861 through Week 16. Both presentations are scheduled for October 21, 2025, and the slides will be made available on Liquidia's website.

Liquidia Corporation (NASDAQ: LQDA) has announced its participation in the Pulmonary Hypertension Professional Association (PHPN) Symposium from September 18-20, 2025, in Seattle. The company will present four posters, including new safety and efficacy data from their ASCENT study of YUTREPIA™ (LIQ861) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The presentations will take place on September 19, 2025, from 3:45-4:30 PM PT, featuring one live thematic poster and three encore presentations. The posters will cover YUTREPIA's impact on cardiac effort, quality of life, patient device usage, and Week 8 safety data from the ASCENT study.

Liquidia Corporation (NASDAQ: LQDA) announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. The company's executive leadership team will conduct a fireside chat on Wednesday, September 3, 2025, at 3:45 p.m. ET in Boston.

Investors and interested parties can access the presentation via webcast through Liquidia's website. A recorded version will remain available for at least 30 days after the event on the company's investor relations page.

Liquidia Corporation (NASDAQ: LQDA) reported significant progress in Q2 2025, highlighted by the successful launch of YUTREPIA™ (treprostinil) inhalation powder. Following FDA approval in May 2025, the drug achieved over 900 unique patient prescriptions and 550 patient starts within 11 weeks for treating PAH and PH-ILD.

The company's interim ASCENT trial data showed promising results, with patients demonstrating a median improvement in six-minute walk distance of 31.5 meters at Week 16. Financially, Liquidia reported $173.4M in cash, generated $6.5M in product revenue, and recorded a net loss of $41.6M ($0.49 per share) for Q2 2025.

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, will release its Q2 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. Investors can access the webcast through Liquidia's website, where it will remain archived for one year.

Liquidia Corporation (NASDAQ: LQDA) has received $50 million from Healthcare Royalty (HCRx) following the first commercial sale of YUTREPIA™ and a favorable court decision denying United Therapeutics' request for an injunction. This funding brings the total received to $175 million out of a potential $200 million under their agreement.

The company plans to use the proceeds to accelerate YUTREPIA's launch, advance its clinical pipeline, and expand manufacturing operations. Management believes Liquidia can achieve profitability without additional capital. The funding terms include a fixed payment schedule through 2033, with aggregate payments capped at 175% of funded amounts and a minimum 13% internal rate of return requirement.

Liquidia Corporation announced its first commercial shipment of YUTREPIA (treprostinil) inhalation powder, following FDA approval on May 23, 2025. The drug is now available for prescription through specialty pharmacies for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company achieved rapid market deployment within five business days of approval, including sales force mobilization and compendia listing. Notably, United Therapeutics' attempt to block YUTREPIA's launch through a preliminary injunction and temporary restraining order was denied by the U.S. District Court, which concluded UTHR was unlikely to succeed in their patent infringement claims regarding U.S. Patent No. 11,357,782.

Liquidia Corporation (NASDAQ: LQDA) has announced that its leadership team will participate in the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York City. The presentation will feature CEO Dr. Roger Jeffs, CFO/COO Michael Kaseta, and CBO Jason Adair in a fireside chat format to provide business updates. Investors can access the webcast through Liquidia's website, where a recording will remain available for at least 30 days after the event.

The FDA has approved Liquidia's (NASDAQ: LQDA) YUTREPIA™, a novel inhalation powder form of treprostinil for treating adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). YUTREPIA is the first prostacyclin dry-powder formulation using Liquidia's proprietary PRINT™ technology, designed for enhanced deep-lung delivery through a low-effort device. The approval is based on the successful Phase 3 INSPIRE trial, which demonstrated safety and tolerability in both treprostinil-naïve patients and those transitioning from nebulized treprostinil. However, United Therapeutics (UTHR) has filed a patent infringement complaint and seeks to block YUTREPIA's commercial launch through a temporary restraining order and preliminary injunction, with the motion currently pending.